369 related articles for article (PubMed ID: 27789382)
21. Early L-dopa, but not pramipexole, restores basal ganglia activity in partially 6-OHDA-lesioned rats.
Marin C; Bonastre M; Mengod G; Cortés R; Giralt A; Obeso JA; Schapira AH
Neurobiol Dis; 2014 Apr; 64():36-47. PubMed ID: 24370700
[TBL] [Abstract][Full Text] [Related]
22. Levodopa induces long-lasting modification in the functional activity of the nigrostriatal pathway.
Riverol M; Ordóñez C; Collantes M; DiCaudo C; Peñuelas I; Arbizu J; Marcilla I; Luquin MR
Neurobiol Dis; 2014 Feb; 62():250-9. PubMed ID: 24076099
[TBL] [Abstract][Full Text] [Related]
23. Antioxidant potential of melatonin enhances the response to L-dopa in 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine-parkinsonian mice.
Zaitone SA; Hammad LN; Farag NE
Pharmacol Rep; 2013; 65(5):1213-26. PubMed ID: 24399717
[TBL] [Abstract][Full Text] [Related]
24. Enhancement of ATP production ameliorates motor and cognitive impairments in a mouse model of MPTP-induced Parkinson's disease.
Haga H; Matsuo K; Yabuki Y; Zhang C; Han F; Fukunaga K
Neurochem Int; 2019 Oct; 129():104492. PubMed ID: 31229554
[TBL] [Abstract][Full Text] [Related]
25. Small molecule TrkB agonist deoxygedunin protects nigrostriatal dopaminergic neurons from 6-OHDA and MPTP induced neurotoxicity in rodents.
Nie S; Xu Y; Chen G; Ma K; Han C; Guo Z; Zhang Z; Ye K; Cao X
Neuropharmacology; 2015 Dec; 99():448-58. PubMed ID: 26282118
[TBL] [Abstract][Full Text] [Related]
26. Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.
Tamim MK; Samadi P; Morissette M; Grégoire L; Ouattara B; Lévesque D; Rouillard C; Di Paolo T
Neuropharmacology; 2010 Jan; 58(1):286-96. PubMed ID: 19576910
[TBL] [Abstract][Full Text] [Related]
27. Dual motor response to l-dopa and nociceptin/orphanin FQ receptor antagonists in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) treated mice: Paradoxical inhibition is relieved by D(2)/D(3) receptor blockade.
Viaro R; Marti M; Morari M
Exp Neurol; 2010 Jun; 223(2):473-84. PubMed ID: 20122926
[TBL] [Abstract][Full Text] [Related]
28. Gypenosides attenuate the development of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Shin KS; Zhao TT; Park KH; Park HJ; Hwang BY; Lee CK; Lee MK
BMC Neurosci; 2015 Apr; 16():23. PubMed ID: 25896846
[TBL] [Abstract][Full Text] [Related]
29. MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates.
Morin N; Grégoire L; Morissette M; Desrayaud S; Gomez-Mancilla B; Gasparini F; Di Paolo T
Neuropharmacology; 2013 Mar; 66():355-64. PubMed ID: 22884464
[TBL] [Abstract][Full Text] [Related]
30. Cinnamon and its Metabolite Protect the Nigrostriatum in a Mouse Model of Parkinson's Disease Via Astrocytic GDNF.
Patel D; Jana A; Roy A; Pahan K
J Neuroimmune Pharmacol; 2019 Sep; 14(3):503-518. PubMed ID: 31119595
[TBL] [Abstract][Full Text] [Related]
31. Melatonin synergizes with low doses of L-DOPA to improve dendritic spine density in the mouse striatum in experimental Parkinsonism.
Naskar A; Manivasagam T; Chakraborty J; Singh R; Thomas B; Dhanasekaran M; Mohanakumar KP
J Pineal Res; 2013 Oct; 55(3):304-12. PubMed ID: 23952687
[TBL] [Abstract][Full Text] [Related]
32. Sitagliptin and Liraglutide Modulate L-dopa Effect and Attenuate Dyskinetic Movements in Rotenone-Lesioned Rats.
Badawi GA; Abd El Fattah MA; Zaki HF; El Sayed MI
Neurotox Res; 2019 Apr; 35(3):635-653. PubMed ID: 30673988
[TBL] [Abstract][Full Text] [Related]
33. L-Dihydroxyphenylalanine modulates the steady-state expression of mouse striatal tyrosine hydroxylase, aromatic L-amino acid decarboxylase, dopamine and its metabolites in an MPTP mouse model of Parkinson's disease.
King JM; Muthian G; Mackey V; Smith M; Charlton C
Life Sci; 2011 Oct; 89(17-18):638-43. PubMed ID: 21871902
[TBL] [Abstract][Full Text] [Related]
34. L-DOPA treatment in MPTP-mouse model of Parkinson's disease potentiates homocysteine accumulation in substantia nigra.
Bhattacharjee N; Mazumder MK; Paul R; Choudhury A; Choudhury S; Borah A
Neurosci Lett; 2016 Aug; 628():225-9. PubMed ID: 27283777
[TBL] [Abstract][Full Text] [Related]
35. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
Hansard MJ; Smith LA; Jackson MJ; Cheetham SC; Jenner P
Mov Disord; 2004 Jan; 19(1):15-21. PubMed ID: 14743355
[TBL] [Abstract][Full Text] [Related]
36. Intervention with 7,8-dihydroxyflavone blocks further striatal terminal loss and restores motor deficits in a progressive mouse model of Parkinson's disease.
Sconce MD; Churchill MJ; Moore C; Meshul CK
Neuroscience; 2015 Apr; 290():454-71. PubMed ID: 25655214
[TBL] [Abstract][Full Text] [Related]
37. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
Rioux L; Frohna PA; Joyce JN; Schneider JS
Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
[TBL] [Abstract][Full Text] [Related]
38. Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset.
Hamadjida A; Nuara SG; Kwan C; Frouni I; Bédard D; Gourdon JC; Huot P
Naunyn Schmiedebergs Arch Pharmacol; 2020 Nov; 393(11):2157-2164. PubMed ID: 32621059
[TBL] [Abstract][Full Text] [Related]
39. L-DOPA disrupts adenosine A(2A)-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: biochemical and behavioral studies.
Pinna A; Bonaventura J; Farré D; Sánchez M; Simola N; Mallol J; Lluís C; Costa G; Baqi Y; Müller CE; Cortés A; McCormick P; Canela EI; Martínez-Pinilla E; Lanciego JL; Casadó V; Armentero MT; Franco R
Exp Neurol; 2014 Mar; 253():180-91. PubMed ID: 24412491
[TBL] [Abstract][Full Text] [Related]
40. L-DOPA-induced behavioral sensitization of motor activity in the MPTP-treated common marmoset as a Parkinson's disease model.
Ando K; Inoue T; Itoh T
Pharmacol Biochem Behav; 2014 Dec; 127():62-9. PubMed ID: 25449794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
